



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
19.01.2022 Bulletin 2022/03

(45) Date of publication and mention
of the grant of the patent:
14.07.2021 Bulletin 2021/28

(21) Application number: **16737859.5**

(22) Date of filing: **14.01.2016**

(51) International Patent Classification (IPC):
C12Q 1/68 (2018.01)

(52) Cooperative Patent Classification (CPC):
C12Q 1/6886; G16B 25/00; G16B 25/10;
G16B 40/00; G16B 40/20; C12Q 2600/158;
C12Q 2600/178

(86) International application number:
PCT/US2016/013353

(87) International publication number:
WO 2016/115312 (21.07.2016 Gazette 2016/29)

(54) **MIRNA-BASED PREDICTIVE MODELS FOR DIAGNOSIS AND PROGNOSIS OF PROSTATE CANCER**

MIRNA-BASIERTE PRÄDIKTIVE MODELLE ZUR DIAGNOSE UND ZUR PROGNOSE VON PROSTATAKREBS

MODÈLES PRÉDICTIFS À BASE DE MICRO-ARN POUR LE DIAGNOSTIC ET LE PRONOSTIC DU CANCER DE LA PROSTATE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **14.01.2015 US 201562103288 P**

(43) Date of publication of application:
22.11.2017 Bulletin 2017/47

(60) Divisional application:
21185398.1

(73) Proprietors:
• **Ohio State Innovation Foundation**
Columbus, OH 43201 (US)
• **Albert-Ludwigs-Universität Freiburg**
79098 Freiburg (DE)

(72) Inventors:
• **CHAKRAVARTI, Arnab**
Dublin, OH 43017 (US)
• **MCKENZIE BELL, Erica**
Columbus, OH 43212 (US)

• **KIRSTE, Simon**
79106 Freiburg (DE)
• **GROSU, Anca-Ligia**
79104 Freiburg (DE)

(74) Representative: **Creek, Isobel Clare**
The IP Asset Partnership Limited
Prima House
267 Banbury Road
Oxford OX2 7HT (GB)

(56) References cited:
WO-A1-2011/127219 WO-A1-2014/085906
WO-A1-2014/085906 WO-A2-2011/082198
WO-A2-2012/015765 US-A1- 2010 179 213
US-A1- 2013 005 837 US-A1- 2013 053 264
US-A1- 2014 309 130

• **R J BRYANT ET AL: "Changes in circulating**
microRNA levels associated with prostate
cancer", BRITISH JOURNAL OF CANCER, vol.
106, no. 4, 14 February 2012 (2012-02-14), pages
768-774, XP055079507, ISSN: 0007-0920, DOI:
10.1038/bjc.2011.595

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- ANNIKA SCHAEFER ET AL: "Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma", INTERNATIONAL JOURNAL OF CANCER, 1 January 2009 (2009-01-01), pages NA-NA, XP055091557, ISSN: 0020-7136, DOI: 10.1002/ijc.24827
- TAO LI ET AL: "miR-21 as an Independent Biochemical Recurrence Predictor and Potential Therapeutic Target for Prostate Cancer", THE JOURNAL OF UROLOGY, vol. 187, no. 4, 1 April 2012 (2012-04-01) , pages 1466-1472, XP055114090, ISSN: 0022-5347, DOI: 10.1016/j.juro.2011.11.082
- BELL ET AL.: 'A Novel MiRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy' PLOS ONE vol. 10, no. 3, 11 March 2015, pages 1 - 19, XP055467452 DOI: 10.1371/JOURNAL.PONE.0118745